Cited by 2,302PARP inhibition in cancer therapyPancreatic and Hepatic Oncology ResearchBRCA gene mutations in cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Open access

Golan, Talia, Hammel, Pascal, Reni, Michele, Van Cutsem, Eric, Macarulla, Teresa, Hall, Michael J., Park, Joon-Oh, Hochhauser, Daniel, Arnold, Dirk, Oh, Do-Youn, Reinacher-Schick, Anke, Tortora, Giampaolo, Algül, Hana, O’Reilly, Eileen M., McGuinness, David, Cui, Karen Y., Schlienger, Katia, Locker, Gershon Y., Kindler, Hedy L.·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1903387PMC PMC6810605

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1903387

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citation
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citation
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 401–500 of 1,002

Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer
Hussung, S., Akhoundova, D., Hipp, J., Follo, M., Klar, R. F. U., Philipp, U., Scherer, F., von Bubnoff, N. C. C., Duyster, J., Boerries, M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07736-x · Cited by 38
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach
Kim, K. B., Soroceanu, L., de Semir, D., Millis, S. Z., Ross, J. S., Vosoughi, E., Dar, A. A., Nosrati, M., Desprez, P., Ice, R. J., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.01.024 · Cited by 38
Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians
Giannis, D., Moris, D., & Barbas, A. S. (2021) · Cancers · doi:10.3390/cancers13051071 · Cited by 37
The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Shen, M., Liu, S., & Stoyanova, T. I. (2021) · PubMed Central · Cited by 36
RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
van Wijk, L. M., Nilas, A. B., Vrieling, H., & Vreeswijk, M. P. G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2020102 · Cited by 41
VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells
Navarro-Carrasco, E., & Lazo, P. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683038 · Cited by 34
Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities
Chakrabarti, S., Kamgar, M., & Mahipal, A. (2022) · Cancers · doi:10.3390/cancers14112588 · Cited by 36
Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
Ulanja, M. B., Moody, A. E., Beutler, B. D., Antwi‐Amoabeng, D., Rahman, G. A., & Alese, O. B. (2022) · Oncotarget · doi:10.18632/oncotarget.28242 · Cited by 38
NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology
Möck, A., Teleanu, M., Kreutzfeldt, S., Heilig, C. E., Hüllein, J., Möhrmann, L., Jahn, A., Hanf, D., Kerle, I. A., Singh, H. M., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00458-w · Cited by 37
A systematic analysis of the landscape of synthetic lethality-driven precision oncology
Schäffer, A. A., Chung, Y., Kammula, A. V., Ruppin, E., & Lee, J. S. (2024) · Med · doi:10.1016/j.medj.2023.12.009 · Cited by 36
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
Russo, T. D. B., Mujacic, C., Giovanni, E. D., Vitale, M. C., Bannera, C. F., Randazzo, U., Contino, S., Bono, M., Gristina, V., Galvano, A., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00815-2 · Cited by 39
The SUMO pathway in pancreatic cancer: insights and inhibition
Schneeweis, C., Hassan, Z., Schick, M., Keller, U. B., & Schneider, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01119-6 · Cited by 36
Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma
Botrus, G., Kosirorek, H., Sonbol, M. B., Kusne, Y. N., Usón, P. L. S., Borad, M. J., Ahn, D. H., Kasi, P. M., Drusbosky, L. M., Dada, H. I., et al. (2021) · The Oncologist · doi:10.1002/onco.13717 · Cited by 36
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
van der Wijngaart, H., Hoes, L. R., Henegouwen, J. M. V. B., van der Velden, D. L., Zeverijn, L. J., Roepman, P., van Werkhoven, E., de Leng, W. W. J., Jansen, A. M. L., Mehra, N., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1104 · Cited by 38
Point/Counterpoint: Is It Time for Universal Germline Genetic Testing for All GI Cancers?
Hampel, H., & Yurgelun, M. B. B. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02764 · Cited by 36
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma
George, B., Kudryashova, O. M., Kravets, A. D., Thalji, S. Z., Malarkannan, S., Kurzrock, R., Chernyavskaya, E. F., Gusakova, M., Kravchenko, D., Tychinin, D. I., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.028 · Cited by 35
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives
Boggi, U., Kauffmann, E. F., Napoli, N., Barreto, S. G., Besselink, M. G., Fusai, G., Hackert, T., Hilal, M. A., Marchegiani, G., Salvia, R., et al. (2024) · Updates in Surgery · doi:10.1007/s13304-024-01860-0 · Cited by 35
Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer
Principe, D. R., Underwood, P. W., Kumar, S., Timbers, K. E., Koch, R. M., Trevino, J. G., Munshi, H. G., & Rana, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.806963 · Cited by 35
Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition
Principe, D. R. (2022) · Cancers · doi:10.3390/cancers14040897 · Cited by 38
Targeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 39
hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
Perera, S., Jang, G. H., Wang, Y., Kelly, D., Allen, M. J., Zhang, A. X. W., Denroche, R. E., Dodd, A., Ramotar, S., Hutchinson, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2576 · Cited by 35
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
Kelly, R. J., Bever, K. M., Chao, J., Ciombor, K. K., Eng, C., Fakih, M., Goyal, L., Hubbard, J. M., Iyer, R. V., Kemberling, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006658 · Cited by 36
Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Park, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1483 · Cited by 34
Self-citation
Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects
García‐Ortiz, M. V., Cano-Ramírez, P., Toledano‐Fonseca, M., Aranda, E., & Rodríguez‐Ariza, A. (2023) · Biomarker Research · doi:10.1186/s40364-023-00528-y · Cited by 35
Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer
de Jesus, V. H. F., Camandaroba, M. P. G., Calsavara, V. F., & Riechelmann, R. P. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920905408 · Cited by 34
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
Silvestris, N., Brunetti, O., Bittoni, A., Cataldo, I., Corsi, D. C., Crippa, S., D’Onofrio, M., Fiore, M., Giommoni, E., Milella, M., et al. (2020) · Cancers · doi:10.3390/cancers12061681 · Cited by 34
Self-citation
Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine inKRASWild-Type Pancreatic Cancer
Fusco, M. J., Saeed‐Vafa, D., Carballido, E. M., Boyle, T. A., Malafa, M. P., Blue, K., Teer, J. K., Walko, C. M., McLeod, H. L., Hicks, J. K., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00265 · Cited by 34
Recent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 36
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
Haas, M., Waldschmidt, D., Ståhl, M., Reinacher-Schick, A. C., Freiberg‐Richter, J., von Weikersthal, L. F., Kaiser, F., Kanzler, S., Frickhofen, N., Seufferlein, T. T. W., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.12.029 · Cited by 34
Self-citation
Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes
Onji, H., & Murai, J. (2022) · Cancer Science · doi:10.1111/cas.15477 · Cited by 38
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants
Macchini, M., Centonze, F., Peretti, U., Orsi, G., Militello, A. M., Valente, M. M., Cascinu, S., & Reni, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102262 · Cited by 34
Self-citation
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 35
Comprehensive review on endoscopic ultrasound-guided tissue acquisition techniques for solid pancreatic tumor
Masuda, S., Koizumi, K., Shionoya, K., Jinushi, R., Makazu, M., Nishino, T., Kimura, K. A., Sumida, C., Kubota, J., Ichita, C., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i12.1863 · Cited by 33
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing
Tung, N., Dougherty, K. C., Gatof, E. S., DeLeonardis, K., Hogan, L., Tukachinsky, H., Gornstein, E. L., Oxnard, G. R., McGregor, K., & Keller, R. B. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00429-1 · Cited by 35
ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I
Li, C., Wang, B., Tu, J., Liu, C., Wang, Y., Chen, J., Huang, Y., Liu, B., & Yuan, X. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06911-3 · Cited by 35
Perspectives on cancer therapy—synthetic lethal precision medicine strategies, molecular mechanisms, therapeutic targets and current technical challenges
Peng, S., Long, M., Chen, Q.-S., Yin, Z., Zeng, C., Zhang, W., Wen, Q., Zhang, X., Ke, W., & Wu, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02418-8 · Cited by 38
Adjuvant and neoadjuvant therapy for pancreatic cancer
Maeda, S., Unno, M., & Yu, J. (2019) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000028 · Cited by 33
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
Bazzichetto, C., Conciatori, F., Luchini, C., Simionato, F., Santoro, R., Vaccaro, V., Corbo, V., Falcone, I., Ferretti, G., Cognetti, F., et al. (2020) · Cells · doi:10.3390/cells9020309 · Cited by 32
Development of circulating tumour DNA analysis for gastrointestinal cancers
Nakamura, Y., & Shitara, K. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000600 · Cited by 33
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
Kieler, M., Unseld, M., Bianconi, D., Schindl, M., Kornek, G. V., Scheithauer, W., & Prager, G. W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030648 · Cited by 33
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
Stein, M. K., Oluoha, O., Patel, K., & Vanderwalde, A. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060518 · Cited by 33
Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer
Cui, J., Jiao, F., Li, Q., Wang, Z., Fu, D., Liang, J., Liang, H., Xia, T., Zhang, T., Zhang, Y., et al. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.08.006 · Cited by 32
“Conversion surgery” for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancreatology (IAP) & Japan Pancreas Society (JPS) 2022
Oba, A., Chiaro, M. D., Fujii, T., Okano, K., Stoop, T. F., Wu, Y. H. A., Maekawa, A., Yoshida, Y., Hashimoto, D., Sugawara, T., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.06.005 · Cited by 32
Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression
Park, S. J., Shin, K., Kim, I.-H., Hong, T. H., Lee, M., Kim, Y., & Suh, J. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165394 · Cited by 34
Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma
Wang, S., Xiong, Y., Luo, Y., Shen, Y., Zhang, F., Lan, H., Pang, Y., Wang, X., Li, X., Zheng, X., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00060-y · Cited by 32
Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease
Gromisch, C. M., Qadan, M., Machado, M. A., Liu, K., Colson, Y. L., & Grinstaff, M. W. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2731 · Cited by 32
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens
Wainberg, Z. A., Feeney, K., Lee, M. A., Martín, A. J. M., Gracián, A. C., Lonardi, S., Ryoo, B., Hung, A., Lin, Y., Bendell, J. C., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07110-x · Cited by 34
Therapeutic response assessment in pancreatic ductal adenocarcinoma: society of abdominal radiology review paper on the role of morphological and functional imaging techniques
Wang, Z. J., Arif‐Tiwari, H., Zaheer, A., Ameli, S., Bhosale, P., Do, R. K., Goenka, A. H., Guimares, A. R., Sangster, G. P., Soloff, E. V., et al. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02723-z · Cited by 33
Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
Dardare, J., Witz, A., Merlin, J., Bochnakian, A., Toussaint, P., Gilson, P., & Harlé, A. (2021) · Pharmaceuticals · doi:10.3390/ph14080740 · Cited by 33
Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting
Pappalardo, A., Giunta, E. F., Tirino, G., Pompella, L., Federico, P., Daniele, B., Vita, F. D., & Petrillo, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695627 · Cited by 32
An appraisal of FDA approvals for adult solid tumours in 2017–2021: has the eagle landed?
Cherny, N. I. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00636-y · Cited by 32
Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System analysis suitability criteria: a single-arm, phase II clinical trial
Hisada, Y., Hijioka, S., Ikeda, G., Maehara, K., Hashimoto, T., Kitamura, H., Harai, S., Yoshinari, M., Kawasaki, Y., Murashima, Y., et al. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01926-z · Cited by 32
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
Shaya, J. A., Kato, S., Adashek, J. J., Patel, H., Fanta, P. T., Botta, G. P., Sicklick, J. K., & Kurzrock, R. (2023) · npj Genomic Medicine · doi:10.1038/s41525-022-00346-5 · Cited by 32
Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine
Vernuccio, F., Messina, C. G. M., Merz, V., Cannella, R., & Midiri, M. (2021) · Diagnostics · doi:10.3390/diagnostics11112166 · Cited by 31
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
Min, K. K. M., Ffrench, C. B., Jessup, C. F., Shepherdson, M., Barreto, S. G., & Bonder, C. S. (2023) · Cancers · doi:10.3390/cancers15082354 · Cited by 35
Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients
Klocker, E. V., Barth, D. A., Riedl, J. M., Prinz, F., Szkandera, J., Schlick, K., Kornprat, P., Lackner, K., Lindenmann, J., Stöger, H., et al. (2020) · Cancers · doi:10.3390/cancers12051154 · Cited by 31
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Roger, É., Gout, J., Arnold, F., Beutel, A. K., Müller, M., Abaei, A., Barth, T. F. E., Rasche, V., Seufferlein, T. T. W., Perkhofer, L., et al. (2020) · Cells · doi:10.3390/cells9092110 · Cited by 31
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair–Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G
Owonikoko, T. K., Redman, M. W., Byers, L. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Bradley, J. D., Stinchcombe, T. E., Leighl, N. B., Baghdadi, T. A., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.001 · Cited by 31
Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma
Askan, G., Şahin, İ. H., Chou, J. F., Yavas, A., Capanu, M., Iacobuzio–Donahue, C. A., Baştürk, O., & O'Reilly, E. M. (2021) · BMC Cancer · doi:10.1186/s12885-021-08123-w · Cited by 31
Self-citation
Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data
Wu, L., Zhu, L., Xu, K., Zhou, S., Zhou, Y., Zhang, T., Hang, J., & Zee, B. C.-Y. (2021) · Journal of Cancer · doi:10.7150/jca.50317 · Cited by 31
Exosomes as Pleiotropic Players in Pancreatic Cancer
Lellis, L. D., Florio, R., Bella, M. C. D., Brocco, D., Guidotti, F., Tinari, N., Grassadonia, A., Lattanzio, R., Cama, A., & Veschi, S. (2021) · Biomedicines · doi:10.3390/biomedicines9030275 · Cited by 31
Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches
Khaddour, K., Maahs, L., Rodriguez, A. M. A., Maamar, Y., Samaan, S., & Ansstas, G. (2021) · Cancers · doi:10.3390/cancers13225847 · Cited by 33
Development of Next-Generation Poly(ADP-Ribose) Polymerase 1–Selective Inhibitors
Ngoi, N. Y. L., Leo, E., O'Connor, M. J., & Yap, T. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000556 · Cited by 32
Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes
Emelyanova, M., Pudova, E. A., Khomich, D., Krasnov, G. S., As, P., Abramov, I. S., Mikhailovich, V. M., Филипенко, М. Л., Menshikova, S., Tjulandin, S. A., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083050 · Cited by 31
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
Olivier, T., Haslam, A., & Prasad, V. K. (2023) · BMC Cancer · doi:10.1186/s12885-023-10917-z · Cited by 33
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Incorvaia, L., Perez, A., Marchetti, C., Brando, C., Gristina, V., Cancelliere, D., Pivetti, A., Contino, S., Giovanni, E. D., Barraco, N., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102650 · Cited by 34
Targeting genome integrity dysfunctions impedes metastatic potency in non–small cell lung cancer circulating tumor cell–derived explants
Tayoun, T., Faugeroux, V., Oulhen, M., Déas, O., Michels, J., Brullé, L., Cairo, S., Scoazec, J., Marty, V., Aberlenc, A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155804 · Cited by 33
Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years
Mosalem, O. M., Abdelhakeem, A. A. F., Abdel-Razeq, N. H., & Babiker, H. M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473698 · Cited by 33
PARPs and PARP inhibitors: molecular mechanisms and clinical applications
Wang, F., Zhuyi, G. U. O., Carr, M. J., & Shi, W. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00385-1 · Cited by 34
Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology
Mweempwa, A., & Wilson, M. K. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.50 · Cited by 32
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design
Passiglia, F., Bironzo, P., Righi, L., Listì, A., Arizio, F., Novello, S., Volante, M., & Scagliotti, G. V. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.07.014 · Cited by 30
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Wang, Y., Park, J. Y. P., Pacis, A., Denroche, R. E., Jang, G. H., Zhang, A. X. W., Cuggia, A., Domecq, C., Monlong, J., Raitses‐Gurevich, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1439 · Cited by 29
Self-citation
PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival
Shao, F., Duan, Y., Zhao, Y., Li, Y., Liu, J., Zhang, C., & He, S. (2021) · Aging · doi:10.18632/aging.202724 · Cited by 31
Targeting Non-Oncogene Addiction for Cancer Therapy
Chang, H. R., Jung, E., Cho, S., Jeon, Y.-J., & Kim, Y. (2021) · Biomolecules · doi:10.3390/biom11020129 · Cited by 30
A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer
Astiazarán-Symonds, E., & Goldstein, A. M. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01806-y · Cited by 34
Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
Hendifar, A. E., Blais, E. M., Wolpin, B. M., Subbiah, V., Collisson, E. A., Singh, I., Cannon, T. L., Shaw, K. R. M., Petricoin, E. F., Klempner, S. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00494 · Cited by 31
Self-citation
PRMT5: An Emerging Target for Pancreatic Adenocarcinoma
Lee, M. K. C., Grimmond, S. M., McArthur, G. A., & Sheppard, K. E. (2021) · Cancers · doi:10.3390/cancers13205136 · Cited by 30
American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence
Calderwood, A. H., Sawhney, M., Thosani, N. C., Rebbeck, T. R., Wani, S. B., Canto, M. I., Fishman, D. S., Golan, T., Hidalgo, M. M., Kwon, R. S., et al. (2022) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2021.12.002 · Cited by 30
Self-citation
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
Zhao, Q., Ma, P., Fu, P., Wang, J., Wang, K., Chen, L., & Yang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.912256 · Cited by 30
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
Liu, K., Geng, Y., Wang, L., Xu, H., Zou, M., Li, Y., Zhao, Z., Chen, T., Xu, F., Sun, L. D., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13279 · Cited by 29
Identification of RAD51–BRCA2 Inhibitors Using N-Acylhydrazone-Based Dynamic Combinatorial Chemistry
Bagnolini, G., Balboni, B., Schipani, F., Gioia, D., Veronesi, M., Franco, F., Kaya, C., Jumde, R. P., Ortega, J. A., Girotto, S., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00063 · Cited by 30
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Marmouset, V., Decroocq, J., Garciaz, S., Étienne, G., Belhabri, A., Bertoli, S., Gastaud, L., Simand, C., Chantepie, S., Uzunov, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1622 · Cited by 30
Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto
Hashimoto, D., Satoi, S., Fujii, T., Sho, M., He, J. P., Hackert, T., Chiaro, M. D., Jang, J., Gulla, A., Yoon, Y., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.07.005 · Cited by 29
Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial
Ohba, A., Ozaka, M., Mizusawa, J., Okusaka, T., Kobayashi, S., Yamashita, T., Ikeda, M., Yasuda, I., Sugimori, K., Sasahira, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.00936 · Cited by 29
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Park, P. H., Yamamoto, T. M., Li, H., Alcivar, A. L., Xia, B., Wang, Y., Bernhardy, A. J., Turner, K. M., Kossenkov, A. V., Watson, Z. L., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0256 · Cited by 30
ATM Serine/Threonine Kinase and its Role in Pancreatic Risk
Nanda, N., & Roberts, N. J. (2020) · Genes · doi:10.3390/genes11010108 · Cited by 30
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
Remón, J., Besse, B., Leary, A. F., Bièche, I., Job, B., Lacroix, L., Auguste, A., Mauduit, M., Audigier-Valette, C., Raimbourg, J., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100068 · Cited by 28
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Marco, M. D., Rodriquenz, M. G., Centonze, F., Rapposelli, I. G., Giordano, G., Vita, F. D., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100032 · Cited by 29
Self-citation
Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, X., Li, Z., & Wang, Y. (2021) · Advanced Biology · doi:10.1002/adbi.201900236 · Cited by 29
Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer
Ku, G. Y., Kemel, Y. M., Maron, S. B., Chou, J. F., Ravichandran, V., Shameer, Z., Maio, A., Won, E. S., Kelsen, D. P., Ilson, D. H., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.14753 · Cited by 29
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis
Lee, Y. S., Lee, J.-C., Kim, J.-H., Kim, J., & Hwang, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-99647-5 · Cited by 29
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer
Carr, T. H., Adelman, C. A., Barnicle, A., Kozarewa, I., Luke, S., Lai, Z., Hollis, S., Dougherty, B. A., Harrington, E. A., Kang, J., et al. (2021) · Cancers · doi:10.3390/cancers13225830 · Cited by 29
Subtyping for pancreatic cancer precision therapy
Huang, X., Zhang, G., & Liang, T. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.005 · Cited by 32
The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling
Umemoto, K., Yamamoto, H., Oikawa, R., Takeda, H., Doi, A., Horie, Y., Arai, H., Ogura, T., Mizukami, T., Izawa, N., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac106 · Cited by 27
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Puccini, A., Seeber, A., & Berger, M. D. (2022) · Cancers · doi:10.3390/cancers14194828 · Cited by 31
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 31
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration
Tsang, E. S., Csizmók, V., Williamson, L. M., Pleasance, E., Topham, J. T., Karasinska, J. M., Titmuss, E., Schrader, K. A., Yip, S. S. F., Tessier‐Cloutier, B., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00368-x · Cited by 26
Clinical and genomic characterisation of early-onset pancreatic cancer
Castet, F., Fabregat-Franco, C., Castillo, G., Navarro, V., Sierra, A., Acosta, D. A., López-Valbuena, D., Dienstmann, R., Tabernero, J. M., Vivancos, A. P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113338 · Cited by 30
Self-citation
Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
da Costa, A. A. B. A., Somuncu, O., Ravindranathan, R., Mukkavalli, S., Martignetti, D. B., Nguyen, H. Q., Jiao, Y., Lamarre, B. P., Sadatrezaei, G., Moreau, L. A., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-4007 · Cited by 29

Authors: Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
Affiliations: Tel Aviv University (IL)
From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
ORCID: Golan, Talia
Hammel, Pascal
Reni, Michele
Macarulla, Teresa
Hall, Michael J.
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Tortora, Giampaolo
Algül, Hana
McGuinness, David
Cui, Karen Y.
Locker, Gershon Y.
Kindler, Hedy L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-07-25
Volume: 381
Issue: 4
Pages: 317-327
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1903387
PMC: PMC6810605
OpenAlex: W2947826965
Cited by: 2,302
References: 24
Citations by year: 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
FWCI: 129.05
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Lirias (submittedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders: AstraZeneca (NA)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
MeSH terms: Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks